Uncategorized Archives - Page 43 of 87 - PsychedelicNewsWire (PNW)

ThursdayMar 25, 2021 3:00 pm

Lifetime Use of Classic Psychedelics Could Decrease Risk of Hypertension

Research recently reported in “Hypertension” has found that lifetime use of classic psychedelics may be associated with a lower risk of hypertension. Otto Simonsson, from University of Oxford’s department of sociology, stated that the findings demonstrated that classic psychedelic use was linked to a 14% lower chance of hypertension, adding that lifetime use of tryptamine was linked to a 20% lower chance of hypertension. Simonsson and his colleagues noted that these results may be valuable in helping understand the physical health after effects of classic psychedelic use, with randomized controlled trials being conducted to look into the possible ways that…

WednesdayMar 24, 2021 12:15 pm

Seattle Doctor Sues DEA over Psilocybin Mushroom Access for Terminally Ill Patients

A doctor from Seattle who hopes to broaden access to hallucinogenic mushrooms for terminally ill cancer patients is suing the U.S. Drug Enforcement Administration (“DEA”) over its recent denial of an application to legally utilize psilocybin mushrooms in end-of-life treatment. The doctor’s attorneys filed the lawsuit last week in the 9th Circuit’s U.S. Circuit Court of Appeals. They argued that the DEA denying the application was baseless. The attorneys are asking judges to dismiss the decision and force the DEA to reconsider and accommodate reasonable requests made from qualified health practitioners for the therapeutic use of psilocybin. On a press…

TuesdayMar 23, 2021 2:45 pm

Scientists Find Ideal Psychedelic Dose for Use in Psychiatric Treatment

Research that was conducted recently to identify the effects of LSD has been reported in the “Neuropsychopharmacology” journal. The discoveries will be used to plan clinical trials that examine the use of LSD in patients with various psychiatric disorders. Prior research had discovered that LSD could be a treatment for some mental conditions when used in combination with psychotherapy. However, these studies compared LSD doses to placebo. Researchers for the new study focused on testing the effects of LSD in different doses. Matthias E. Liechti, a researcher from the University Hospital Basel, stated that the group or researchers wanted to…

MondayMar 22, 2021 11:38 am

Pure Extracts Technologies Corp.’s (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Subsidiary Pure Mushrooms Corp. Submits Application to Health Canada for a Dealer’s License

Pure Extracts Technologies Corp.’s subsidiary Pure Mushrooms Corp. has submitted an application to Health Canada for a Dealer’s License Award of a Dealer’s License will enable company to procure controlled substances, conduct research, carry out business-to-business sales Pure Extracts has recently commenced a study into psilocybin-based active treatments, with research set to be carried out under auspices of Toronto Institute of Pharmaceutical Technology Functional mushroom, psychedelic drug market is forecast to grow to value of $6.85 billion by 2027 Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, functional mushrooms and…

MondayMar 22, 2021 10:15 am

Study Finds Users of Psychedelics Have Better Physical Health Than Non-Users

Recent research has found that using psychedelic substances has been linked to better physical health. However, the cause of the link between the two is still not clear. The study’s corresponding author, Otto Simonsson, stated that while a lot of research on classic psychedelics had shown the various mental health benefits they possessed, little was known about how these psychedelics may impact long-term physical health outcomes. Simonsson, who is from the University of Oxford, added that he was curious to find out. For purposes of their research, the researchers examined data collected from 171,766 individuals who responded to surveys conducted…

FridayMar 19, 2021 1:00 pm

European Firms May Dominate Psychedelics Market in Foreseeable Future

Most pioneering research on the potential of psychedelics to treat various mental health conditions has originated from the United States. In the 1950s, Humphry Osmond, a psychiatrist from California, started experimenting with LSD, a psychedelic drug that he administered to patients. MAPS, a leading not-for-profit organization that conducts research on psychedelics, was established in the late 1980s in the United States. However, with regard to commercializing psychedelics to help treat various disorders such as addiction and depression, it is not American but European companies that are at the forefront. The last year can attest to this. Last year, a biotech…

ThursdayMar 18, 2021 2:00 pm

Former Australian Defense Chief Advocates for Psychedelic Drugs to Be Rescheduled

Advocates calling for psychedelic-assisted therapy had in 2020 applied to reschedule psychedelic drugs under controlled drugs from prohibited substances. The drugs include oxycodone, methadone and morphine. Last month, the Therapeutic Goods Administration issued an interim decision to not revise the Poisons Standard, which would have allowed mental health professionals access to the drugs. Retired Admiral Christopher Barrie, who was the Defense Forces Chief from 1998–2002, stated that psychedelic drugs such as MDMA and psilocybin should be reclassified so that they could be used to treat mental health conditions such as PTSD and depression. Barrie is the director of Mind Medicine…

WednesdayMar 17, 2021 3:10 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Takes Milestone Step Toward Offering Product Across Canada

PULL subsidiary has submitted application to Health Canada to amend license to permit sales of product The submission follows recent announcement that Pure Extracts inked distribution agreement with an important Canadian Licensed Producer (“LP”) PULL plans on distributing exclusive vape, edible products to retail buyers across Canada As a result of the its recently inked distribution agreement with an important Canadian LP, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) through its wholly owned subsidiary, Pure Extracts Manufacturing Corp., will be selling its exclusive, high-quality cannabis extract products to provincially authorized distributors and retailers throughout Canada by the end of April.…

WednesdayMar 17, 2021 2:15 pm

Veterans’ Groups Demand Access to Psychedelics, Marijuana Through VA

Leaders of various military veterans’ organizations have issued a message to congressional legislators stating that federal psychedelics and cannabis laws were out of date and needed to be reformed. This, they said, would provide service members with alternative treatment options for conditions such as PTSD. Additionally, three veterans service organizations presented written testimonies during the House and Senate Veterans Affairs Committees hearings recently. The testimonies supported a change in policy that would allow more research to be conducted on medical marijuana and broaden access to medical marijuana, with another arguing that loosening restrictions would allow veterans to use psychedelics as…

MondayMar 15, 2021 2:45 pm

Global Survey Discovers Many People Are Self-Medicating with Psychedelics

A survey conducted recently that includes 110,000 individuals who answered various questions that focused on their use of drugs, found that roughly 6% of them used psychedelics to deal with their mental health issues and emotional issues. The survey found that the drugs most commonly used by the percentage which represented about 6,500 individuals, were ketamine, psilocybin, MDMA and LSD. The Global Drug Survey 2020 included examples of people microdosing on psilocybin mushrooms or LSD on their own, as well as instances where psychedelics were consumed in a way that was unregulated but under the keen eye of another individual.…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized